MA25089A1 - Formulations intranasales de mesylate de sildenafil et procede pour leur preparation - Google Patents

Formulations intranasales de mesylate de sildenafil et procede pour leur preparation

Info

Publication number
MA25089A1
MA25089A1 MA25639A MA25639A MA25089A1 MA 25089 A1 MA25089 A1 MA 25089A1 MA 25639 A MA25639 A MA 25639A MA 25639 A MA25639 A MA 25639A MA 25089 A1 MA25089 A1 MA 25089A1
Authority
MA
Morocco
Prior art keywords
preparation
intranasal formulations
sildenafil mesylate
sildenafil
mesylate
Prior art date
Application number
MA25639A
Other languages
English (en)
Inventor
James Dunn Peter
Jayne Woods Joanna
Thomas Henry Brian
Billotte Anne
Vallance Marshall Peter
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of MA25089A1 publication Critical patent/MA25089A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25639A 1998-06-22 1999-06-21 Formulations intranasales de mesylate de sildenafil et procede pour leur preparation MA25089A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MA25089A1 true MA25089A1 (fr) 2000-12-31

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25639A MA25089A1 (fr) 1998-06-22 1999-06-21 Formulations intranasales de mesylate de sildenafil et procede pour leur preparation

Country Status (40)

Country Link
US (2) US20020040139A1 (fr)
EP (1) EP0967214B1 (fr)
JP (1) JP3263379B2 (fr)
KR (1) KR100345824B1 (fr)
AP (1) AP1178A (fr)
AR (1) AR016993A1 (fr)
AT (1) ATE269866T1 (fr)
AU (1) AU746865B2 (fr)
BG (1) BG64372B1 (fr)
BR (1) BR9903273A (fr)
CA (1) CA2275554C (fr)
CZ (1) CZ294856B6 (fr)
DE (1) DE69918222T2 (fr)
DK (1) DK0967214T3 (fr)
DZ (1) DZ2826A1 (fr)
EA (1) EA001903B1 (fr)
ES (1) ES2221733T3 (fr)
GT (1) GT199900095A (fr)
HN (1) HN1999000096A (fr)
HR (1) HRP990195B1 (fr)
HU (1) HUP9902076A3 (fr)
ID (1) ID23554A (fr)
IL (1) IL130539A0 (fr)
IS (1) IS5085A (fr)
MA (1) MA25089A1 (fr)
MY (1) MY117967A (fr)
NO (1) NO317365B1 (fr)
NZ (1) NZ336382A (fr)
OA (1) OA11069A (fr)
PA (1) PA8476301A1 (fr)
PE (1) PE20000702A1 (fr)
PT (1) PT967214E (fr)
SG (1) SG77246A1 (fr)
SI (1) SI0967214T1 (fr)
SK (1) SK284574B6 (fr)
TN (1) TNSN99129A1 (fr)
TR (1) TR199901444A2 (fr)
TW (1) TWI223598B (fr)
UA (1) UA59385C2 (fr)
YU (1) YU29699A (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2391968A1 (fr) * 1999-11-18 2001-05-25 Natco Pharma Limited Composition pharmaceutique amelioree pour traiter la dyserection masculine
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
CA2446904A1 (fr) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Administration d'esters medicamenteux par inhalation
WO2002094219A2 (fr) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Administration par voie pulmonaire de medicaments contre les troubles de l'erection
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
WO2004073729A1 (fr) 2003-02-21 2004-09-02 Translational Research Ltd. Compositions destinees a l'administration nasale d'un medicament
CA2519287A1 (fr) 2003-03-27 2004-10-14 Bioactis Limited Applicateur de medicament en poudre pour cavite nasale
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
EP1625333A1 (fr) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Unite de chauffage autonome et unite de fourniture de medicament faisant appel a cette unite de chauffage
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006016530A1 (fr) * 2004-08-10 2006-02-16 Translational Research, Ltd. Composition transnasale dont l’action est immédiate et l’absorbabilité est élevée
EP2246086A3 (fr) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Dispositif d'administration de médicament en aérosol comprenant une unité de chauffage allumée par percussion
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
AU2005296719B2 (en) 2004-10-18 2011-02-03 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
WO2006094924A2 (fr) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'inhibiteurs de pde 5
NZ561746A (en) 2005-04-19 2011-09-30 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2008518041A (ja) * 2005-08-29 2008-05-29 テバ ファーマシューティカル インダストリーズ リミティド 双峰性粒度分布を有する固体微粒子タダラフィル
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2009098697A1 (fr) * 2008-02-08 2009-08-13 Dexxon Ltd. Formes pharmaceutiques de modafinil et de sildénafil
CA2756690C (fr) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration de compositions de benzodiazepine
CN102056568B (zh) 2008-06-04 2013-08-21 高露洁-棕榄公司 具有气穴系统的口腔护理器具
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
CA2798884C (fr) 2010-05-10 2016-09-13 Euro-Celtique S.A. Fabrication de granules sans principe actif et comprimes les comprenant
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
EP4085899A1 (fr) 2011-06-14 2022-11-09 Neurelis, Inc. Administration de benzodiazépine
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (fr) * 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
CA2881144A1 (fr) * 2012-11-09 2014-05-09 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
EP2968204B1 (fr) * 2013-03-15 2019-05-15 Robert I. Henkin Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
WO2015071380A1 (fr) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
NO2723977T3 (fr) 2014-03-19 2018-03-10
US20170035764A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
BR112019008565A2 (pt) * 2016-10-31 2019-07-09 Suda Ltd distribuição do agente ativo na mucosa
JP7143335B2 (ja) 2017-03-02 2022-09-28 ダッチ・リニューアブル・エナジー・ビー．ブイ． 生理活性物質の鼻腔内投与
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019130052A1 (fr) * 2017-12-26 2019-07-04 Ftf Pharma Private Limited Formulations orales liquides pour inhibiteurs de pde v
EP3746138B1 (fr) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Dispositif aérosol à condensation électrique
WO2019157099A1 (fr) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Formulations d'épinéphrine intranasale et méthodes de traitement d'une maladie
WO2019200427A1 (fr) 2018-04-16 2019-10-24 Barista Mist Pty Ltd Compositions de caféine et procédés d'utilisation
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
US20220111162A1 (en) * 2020-07-29 2022-04-14 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient
CN117580579A (zh) 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
YU49315B (sh) * 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
AU739417B2 (en) * 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
WO1999027905A1 (fr) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions pour administration nasale
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
BG64372B1 (bg) 2004-12-30
IL130539A0 (en) 2000-06-01
CZ9902257A3 (cs) 2000-11-15
ID23554A (id) 2000-05-04
IS5085A (is) 1999-12-23
CZ294856B6 (cs) 2005-03-16
CA2275554A1 (fr) 1999-12-22
AU746865B2 (en) 2002-05-02
HRP990195A2 (en) 2000-02-29
DK0967214T3 (da) 2004-09-27
EA001903B1 (ru) 2001-10-22
BG103510A (en) 2000-01-31
PA8476301A1 (es) 2000-09-29
SG77246A1 (en) 2000-12-19
SI0967214T1 (en) 2004-10-31
EP0967214A1 (fr) 1999-12-29
EA199900487A3 (ru) 2000-04-24
JP3263379B2 (ja) 2002-03-04
ATE269866T1 (de) 2004-07-15
SK81999A3 (en) 2001-01-18
UA59385C2 (uk) 2003-09-15
HU9902076D0 (en) 1999-08-30
US20030158206A1 (en) 2003-08-21
AR016993A1 (es) 2001-08-01
EA199900487A2 (ru) 1999-12-29
PT967214E (pt) 2004-08-31
HUP9902076A2 (hu) 2000-05-28
KR20000006310A (ko) 2000-01-25
DZ2826A1 (fr) 2003-12-01
BR9903273A (pt) 2000-05-09
NZ336382A (en) 1999-11-29
KR100345824B1 (ko) 2002-07-24
EP0967214B1 (fr) 2004-06-23
CA2275554C (fr) 2003-06-03
HN1999000096A (es) 2000-12-03
SK284574B6 (sk) 2005-06-02
AP9901585A0 (en) 1999-06-30
HUP9902076A3 (en) 2002-03-28
TR199901444A2 (xx) 2000-01-21
YU29699A (sh) 2003-02-28
NO993051D0 (no) 1999-06-21
DE69918222D1 (de) 2004-07-29
US20020040139A1 (en) 2002-04-04
JP2000034232A (ja) 2000-02-02
AU3579499A (en) 2000-01-06
TNSN99129A1 (fr) 2005-11-10
NO993051L (no) 1999-12-23
TWI223598B (en) 2004-11-11
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01
HRP990195B1 (en) 2003-04-30
MY117967A (en) 2004-08-30
PE20000702A1 (es) 2000-08-16
AP1178A (en) 2003-06-30
GT199900095A (es) 2000-12-13
NO317365B1 (no) 2004-10-18
OA11069A (en) 2002-03-13

Similar Documents

Publication Publication Date Title
MA25089A1 (fr) Formulations intranasales de mesylate de sildenafil et procede pour leur preparation
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA24205A1 (fr) Procede pour la preparation du sildenafil
MA24747A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
FR2748026B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0104582A3 (en) 1,2-annelated quinoline derivatives, pharmaceutical compositions thereof, intermediates and process for their preparation
NO20013039D0 (no) Apparat og fremgangsmåte for fremstilling av krystallinske partikler
AP2001002183A0 (en) Ethanolate of zithromycin process for manufacture and pharmaceutical compositions thereof
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2807052B1 (fr) Compositions silico-acryliques, leur procede de preparation et leur utilisation
EP1222865A4 (fr) Ingredient pour cigarette et procede de fabrication
FR2781801B1 (fr) Procede pour la preparation de dianhydride pyromellique
FR2818979B1 (fr) Procede de preparation d'imidaclopride
FR2753204B1 (fr) Procede de preparation d'adn plasmidique
FR2773558B1 (fr) Procede pour l'obtention de 1-butene
PL337502A1 (en) Apparatus for collecting foreign matter discovered during tillage of plough-land
MA26710A1 (fr) Formulations de doramectine antiparasitaires et procede pour leur preparation
IL142589A0 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
FR2768725B1 (fr) Procede de preparation du 2-chloroprop-1-ene
HUP9904030A3 (en) Use of tiagabine for production of pharmaceutical against psychotic disorders
MA24834A1 (fr) Halogenures de phenoxyphenysulfonyle et procede pour leur preparation
MA23966A1 (fr) Formes zwitterioniques de trovafloxacine , procede pour leur preparation et compositions les contenant
FR2805535B1 (fr) Nouveau procede de preparation de l'isoindoline
FR2792532B1 (fr) Nouvelles compositions antiseptiques et leur procede d'obtention
EP1120100A4 (fr) Agents antibacteriens et leur procede de preparation